MTIM
ARCT icon

Marathon Trading Investment Management’s Arcturus Therapeutics ARCT Stock Holding History

Marathon Trading Investment Management’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-1,429
Closed -$37K – 469
2014
Q4 		$37K Buy
+1,429
New +$45.4K ﹤0.01% 512

Other funds holding ARCT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
TI
Turner Investments Berwyn, Pennsylvania $134K AUM 49.03% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Marathon Trading Investment Management's ARCT Position: Q1 2015 in Review

Marathon Trading Investment Management sold out of Arcturus Therapeutics (ARCT) in Q1 2015, closing a stake of 1,429 shares — an estimated $37K sold.

Marathon Trading Investment Management first reported a position in ARCT in Q4 2014 and held it in 1 quarter. The position peaked at $37K in Q4 2014. 28 funds tracked by Wall St. Rank hold ARCT as of Q1 2015.

  • Marathon Trading Investment Management reported no remaining Arcturus Therapeutics position as of Q1 2015 after selling out during the quarter.
  • Marathon Trading Investment Management sold 1,429 Arcturus Therapeutics shares in Q1 2015, an estimated $37K.
  • Marathon Trading Investment Management first reported a position in Arcturus Therapeutics in Q4 2014 and held it in 1 quarter.
  • Marathon Trading Investment Management's Arcturus Therapeutics position peaked at $37K in Q4 2014.
  • 28 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2015.

Based on Marathon Trading Investment Management's 13F filing for Q1 2015, filed 12 May 2015.